→ Robo
1 known investors
Robo is an AI platform that automates research and evaluation of external biopharma assets, using AI agents to search across 100M+ primary data sources such as publications, trial registries, patents, and conference abstracts and score them against custom criteria. It serves business development and research teams in the biopharma industry.
Also known as Robo
Investors · 1
Company profile
researched Aug 2026Robo (robo.tech) offers an AI platform for end-to-end automation of research on external assets in the biopharma sector. Users define a project by outlining objectives in natural language, including complex, multi-part criteria; the platform converts that mandate into tailored search and evaluation AI agents. Those agents research across what the company describes as more than 100 million primary data sources, including publications, trial registries, patents and conference abstracts, and evaluate each asset against the user's custom criteria before assigning a relevance score.
The product includes iterative review and refinement, in which users scan top results, adjust parameters and narrow a shortlist, with feedback fed back into the agents to reflect user priorities. It also provides ongoing monitoring, refreshing asset profiles and evaluations as new data becomes available so that a brief remains active over time. The company positions the platform as enterprise-grade and purpose-built for nuanced, mission-critical asset research.
Business model
The site markets the platform to enterprise biopharma teams and directs prospects to book a demo; no pricing or contracting details are disclosed in the available sources.
Latest developments
The company's website states it is early in its roadmap ('we're just getting started'); no dated developments are documented in the sources.
▸Full profile — market position, technology, go-to-market
Market position
Positions itself as an enterprise AI tool for biopharma asset search and evaluation, an alternative to static licensed databases and general-purpose AI assistants.
The company contrasts its approach with static legacy databases, which it says do not support the underlying work, and with generic AI tools, which it says hallucinate and cover only narrow slices of the asset landscape. It emphasizes purpose-built, end-to-end automation and evaluation with stated PhD-level rigor.
Technology
AI agents generated from a user's natural-language mandate that search across a stated 100M+ primary data sources (publications, trial registries, patents, conference abstracts), score assets against custom criteria, incorporate user feedback to refine results, and re-run as new data appears.
Go-to-market
Direct enterprise sales motion driven from the website, with 'Book a Demo' as the primary call to action and a product walkthrough section.
Business teams in biopharma responsible for identifying and evaluating external assets, such as business development and research functions.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 6
primary sources listed
- → Roborobo.tech · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does → Robo do?
- Robo is an AI platform that automates search, evaluation and scoring of external biopharma assets for business development teams.
- Who are → Robo's investors?
- → Robo's investors include El Cap Equity.